A UAB study sheds light on and suggests a target for treatment of a variant of Guillain-Barré syndrome.

An NIH grant will help support personalized medicine and patient-oriented research at UAB.
Published in Faculty Excellence
The mechanism of widespread reorganization of DNA methylation may be a therapeutic target to prevent or reverse dyskinesia.
The biomarker, the protein kinase LRRK2, is a promising candidate for future exploration.
Results show that JAK/STAT pathway inhibitors may be a new class of therapeutic treatments for patients with Parkinson’s disease. Acting by reducing inflammation, they prevent neurodegeneration in animal models and may be an important new approach to slow progression of the disease.
UAB joins with leading Parkinson’s disease organizations for a Birmingham conference.
Published in Service to Community
Preliminary results from UAB’s CBD oil studies show benefit in seizure control in some patients.
A key role for microRNA-155 in brain inflammation and neurodegeneration makes it both a potential therapeutic target and a biomarker for this progressive disorder.
Alabama ALS chapter honors UAB’s Peter King with Spirit of Lou Gehrig Award.
Published in Faculty Excellence
More evidence that generic medications are as effective as brand name drugs.
UAB-led research shows how methylating an RNA binding protein leads to alternative RNA splicing. Mutant enzymes are often found in blood cancers.
Best of 2015 2The UAB studies are designed to test the safety and tolerability of CBD oil in patients with intractable seizures. CBD oil, a derivative of the cannabis plant, is delivered orally as an oily liquid.
Published in Focus on Patient Care
The Alzheimer’s plaques that accumulate around brain cells also congregate along the walls of blood vessels, according to UAB research, and that may contribute to cognitive issues.
Engineers, physicians, computer scientists and statisticians will collaborate to research and apply big data in the health care, industrial and smart cities fields.
A multisite study led by UAB has found the first biomarker for the onset of seizures in infants with tuberous sclerosis.
UAB's strengths in clinical care and research are powering an interdisciplinary expedition into largely uncharted territory: neuroinflammatory mechanisms in Parkinson's disease.

UAB’s Roberson wins young investigator award from the American Neurological Association.

Published in Faculty Excellence
Oh honored with lifetime award from the American Association of Neuromuscular and Electrodiagnostic Medicine.
Published in Faculty Excellence
Haydeh Payami, Ph.D., a leading geneticist recruited to the UAB-Hudson Alpha Center for Genomic Medicine and UAB Personalized Medicine Institute, is exploring the protective power of coffee and nicotine — and the mysteries of the microbiome — in Parkinson’s disease.
The drug inhibits the activity of a kinase enzyme called LRRK2, and it showed no pathology in rat lungs, kidneys or livers.
Page 1 of 6
Back to Top